Accelerating drug approval with Simoa® ultrasensitive measurements of biomarkers

Simoa^®is a digital immunoassay technology that enables the measurement of ultra-low levels of biomarkers. Leveraging small sample volume requirements and efficient workflows, Simoa^® instruments and assays, including those used for phosphorylated tau and neurofilament light, have been widely used in clinical drug trials for the study of neurological disorders, such as Alzheimer's disease and Multiple Sclerosis. Both assays have gained breakthrough device designation by the FDA and are available as clinical laboratory improvement amendments (CLIA) regulated laboratory developed tests (LDTs) at Quanterix. Simoa^® technology extends beyond neurology and supports applications in oncology, inflammation, and infectious diseases.

In this webinar, Dr. Milena Milutinovic from Quanterix and Dr. Nicholas Ashton from the University of Gothenburg, will discuss how Simoa^®technology continues to be essential in the identification and validation of novel biomarkers. Plus, find out how this technology holds the potential to transform the drug approval process and patient management.

Dr. Ashton will also highlight the gaps in blood biomarker research and share how his work is addressing this need. The webinar will then demonstrate how Simoa technology is advancing neurological research and the clinical utility of blood-based biomarkers.

Key learning objectives

Discover how immunoassays are used to monitor circulating protein biomarkers
Learn more about immunoassays and how they serve as a scalable solution for patient-centric trials, but often lack sensitivity for high sample readability
Explore the Simoa^® technology that enables the digital measurement of ultralow levels of biomarkers
Find out how to identify optimal blood biomarkers for use in clinical routine and clinical trials
Explore the current research working to close the gaps in the blood biomarker field

Who should attend?